Journal
MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume -, Issue -, Pages -Publisher
SPRINGER
DOI: 10.1007/s11010-023-04841
Keywords
Sepsis; SIRS; Sepsis shock; m6A modification
Categories
Ask authors/readers for more resources
N6-methyladenosine (m6A) modification is a type of epitope modification that has gained attention for its role in diseases, including sepsis. Recent epigenetic research has focused on m6A modifications, which are regulated by three types of proteins: Writers (such as METTL3/METTL14/WTAP) responsible for modification, Erasers (FTO and ALKBH5) involved in de-modification, and Readers (YTHDC1/2, YTHDF1/2/3) responsible for recognition. This review summarizes recent studies on the involvement of m6A and its regulators in sepsis, highlighting their potential value in diagnosis, treatment, and prognosis.
N6-methyladenosine (m6A) modification is a class of epitope modifications that has received significant attention in recent years, particularly in relation to its role in various diseases, including sepsis. Epigenetic research has increasingly focused on m6A modifications, which is influenced by the dynamic regulation of three protein types: ‟Writers (such as METTL3/METTL14/WTAP)-responsible for m6A modification; ‟Erasers (FTO and ALKBH5)-involved in m6A de-modification; and ‟Readers (YTHDC1/2, YTHDF1/2/3)-responsible for m6A recognition. Sepsis, a severe and fatal infectious disease, has garnered attention regarding the crucial effect of m6A modifications on its development. In this review, we attempted to summarize the recent studies on the involvement of m6A and its regulators in sepsis, as well as the significance of m6A modifications and their regulators in the development of novel drugs and clinical treatment. The potential value of m6A modifications and modulators in the diagnosis, treatment, and prognosis of sepsis has also been discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available